Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Sponsor
Novo Nordisk A/S
Study ID
NCT01821846
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).

Study Details

This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.

Key Dates

Start date
Nov 20, 2013
Status verified
Aug 2017
Primary completion
Mar 8, 2017
Completion
Mar 8, 2017

Study Design

Enrollment
64 participants (actual)

Arms

  • Arm: Liraglutide

Primary Outcome Measure

The incidence of SADRs (Serious Adverse Drug Reactions) [ Time Frame: Up to 6 months ]

Related Studies